Stephen Industries is pleased to have participated in Gesynta Pharma’s latest financing round to support the development of a non-hormonal drug candidate for the treatment of endometriosis.

Endometriosis, a painful chronic inflammatory disease that affects the health and quality of life of more than 10% of women of reproductive age.

Gesynta Pharma is developing vipoglanstat, a novel non-hormonal drug candidate for the treatment of endometriosis. Vipoglanstat targets mPGES-1, an enzyme upregulated in endometriotic lesions that drives both pain and lesion progression.

Learn more at: www.gesynta.se